phase readout

NCT05436418: The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

RECRUITINGupdated 2mo ago

community read0 votes

Sponsor: National Cancer Institute (NCI). Phase: PHASE1. Conditions: Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation

view source ↗

NCT05436418: The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Report a data issue

comments(0)